The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post‐menopausal women

@article{OrrWalker1998TheEO,
  title={The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post‐menopausal women},
  author={B. Orr-Walker and M. Evans and R. Ames and J. Clearwater and T. Cundy and I. Reid},
  journal={Clinical Endocrinology},
  year={1998},
  volume={49}
}
Depot medroxyprogesterone acetate (DMPA), an injectable progestogen, is a widely used contraceptive acting primarily by inhibiting secretion of pituitary gonadotrophins, thus producing oestrogen deficiency. Cross‐sectional and prospective studies in pre‐menopausal women have shown DMPA use to be associated with reduced bone density, but bone density increases following discontinuation of the drug. Because fracture rates are low in pre‐menopausal women, the principal concern arising from the… Expand
Update on hormonal contraception and bone density
Progestin-Only Contraception and Bone Health
  • M. Isley
  • Medicine
  • Current Obstetrics and Gynecology Reports
  • 2017
Depo-Provera® and bone density
  • B. Gbolade
  • Medicine
  • Journal of Family Planning and Reproductive Health Care
  • 2002
Bone density recovery after depot medroxyprogesterone acetate injectable contraception use.
Depot-medroxyprogesterone acetate: an update
...
1
2
3
4
5
...

References

SHOWING 1-6 OF 6 REFERENCES
A prospective evaluation of depo-medroxyprogesterone acetate contraception on bone mineral density in young women
  • Journal of Bone and Mineral Research
  • 1997
Depo-medroxyprogesterone acetate exposure and stress fractures in female military recruits
  • Journal of Bone and Mineral Research
  • 1997